NAD+ Patches vs Injections: What the Evidence Shows
What You Should Know
- Both patches and injections deliver NAD+ as a molecule that cannot cross cell membranes intact.
- No published clinical trials have demonstrated that NAD+ patches or subcutaneous injections raise intracellular NAD+ levels.
- NAD+ is an intracellular molecule, and the relevant target is levels inside your cells (40–100 μM), not blood concentration.
- Clinical trial data shows a well-formulated oral precursor supplement can outperform subcutaneous injections on the only measure that actually matters.
If you’ve been researching NAD+ supplementation, patches and injections probably caught your attention. They sound more clinical than a powder you stir into water. More direct. More serious.
The appeal makes sense. Both methods promise to bypass digestion and deliver NAD+ straight into your bloodstream. For something as important as cellular energy, that sounds like an upgrade over a capsule.
Here’s what most comparisons leave out: getting NAD+ into your blood is not the same as getting it into your cells. And the research on whether patches or injections accomplish the latter is thinner than most people realize.
CLIA-Certified NAD Blood Test
Test your intracellular NAD+ levels from home.

Why People Turn to NAD Patches and Injections in the First Place
The logic behind both methods is intuitive. Oral supplements have to survive digestion before anything useful reaches your bloodstream. If you can skip that step, you should end up with more NAD+ available for your cells. On paper, patches and injections seem like the smarter route.
It’s a reasonable conclusion. But it rests on an assumption worth examining: that the NAD+ delivered into your blood actually ends up where it needs to go.
This section covers how each method works before we get to what the evidence says about whether either one is doing what people assume.
How NAD+ Patches Work
NAD+ patches are worn on the skin, typically on the upper arm, inner wrist, or abdomen. They release NAD+ gradually through the skin over 12 to 14 hours. Some use passive diffusion, while others use iontophoresis technology, which applies a mild electrical current to push molecules through the skin barrier more actively.
The appeal is convenience. No needles, no clinic visit, no scheduled appointments. You apply the patch and go about your day. Depending on the brand, patches contain anywhere from 400mg to over 1,000mg of NAD+.
How NAD+ Injections Work
NAD+ injections are administered subcutaneously (just beneath the skin into fatty tissue) or intramuscularly. Both routes bypass the digestive system entirely, delivering NAD+ directly into tissue near the bloodstream.
Subcutaneous doses are typically in the 50 to 200mg range, given two to three times per week. Intramuscular injections absorb faster and allow for slightly larger volumes. Most protocols require a clinic visit or physician oversight, though some providers have moved toward at-home self-injection kits. For a complete breakdown of how each injection route works, our overview of NAD+ injections covers the key differences.
The Core Problem Both Methods Share
Before comparing patches to injections against each other, there is a more important question worth answering first: does either method actually raise NAD+ inside your cells?
This is where most comparison articles stop short.
NAD+ Is Too Large to Cross Cell Membranes
NAD+ is an intracellular molecule. It does not naturally circulate in the bloodstream in meaningful amounts, and there is a clear biological reason for that: the NAD+ molecule is too large to cross cell membranes intact.
Dr. Eric Verdin, President of the Buck Institute for Research on Aging, has stated this directly: “NAD+ is too big to enter cells and is mostly broken down into nicotinamide when injected. Oral precursors like NMN or NR are a better bet for most people.”
Research published in Science Advances on NAD+ precursor synthesis pathways confirms that even intravenously administered NAD+ is rapidly broken down into smaller metabolites before reaching intracellular targets. A study in Metabolites examining extracellular NAD+ metabolism in human cells found that dinucleotides and mononucleotides are degraded by blood enzymes to nucleosides before cells can absorb them.
Delivering NAD+ into your bloodstream does not reliably translate into raising NAD+ inside your cells.
What “Bioavailability” Actually Means for NAD+
Most discussions of patches versus injections focus on bioavailability in terms of how much NAD+ reaches your blood. That is the wrong metric.
The relevant target for NAD+ is intracellular concentration, measured in micromoles (μM). According to Dr. Jin-Xiong She, founder of Jinfiniti Precision Medicine and a genomic researcher with over 400 peer-reviewed publications, the optimal intracellular NAD+ range is 40 to 100 μM. Levels below 40 μM are associated with fatigue, slower recovery, and reduced cellular repair capacity. Levels above 100 μM are not associated with additional benefit and may carry risk.
A 2019 pilot study in Frontiers in Aging Neuroscience found that urinary NAD+ levels jumped 538% during a six-hour IV infusion, meaning a substantial portion of what was delivered passed through the body without being used at the cellular level. Raising the number in your blood is not the same as raising it where it does anything useful.
To understand what intracellular NAD+ actually does in the body, starting with the fundamentals of how NAD+ functions at the cellular level gives useful context.
Comparing Patches and Injections Side by Side
With the core limitation in mind, here is how the two methods compare across the factors that matter most.
| NAD+ Patches | NAD+ Injections | |
|---|---|---|
| Clinical trials (humans) | No published RCTs | No published RCTs for SC/IM |
| Intracellular efficacy | Not established | Not established |
| Cost | $15–80 per patch | $50–200 per session |
| Convenience | High (at-home) | Low to moderate |
| Common side effects | Skin irritation | Injection site reactions, nausea |
| Medical supervision | Not typically required | Often required |
Both columns share the same most important row: no published randomized controlled trials demonstrating intracellular NAD+ improvement.
The Evidence Gap for NAD+ Patches
The research on NAD+ patches specifically is sparse. As a review by Bolt Pharmacy found, no peer-reviewed human clinical trials have evaluated the efficacy of NAD+ patches, and bioavailability through intact skin remains unestablished. There is no published pharmacokinetic data measuring blood NAD+ levels following patch application, let alone intracellular levels.
The iontophoresis technology used in some patches is legitimate and has real medical applications. Whether it can meaningfully push NAD+ molecules through skin and into cells is a separate question, and it remains unanswered by the published literature.
The Evidence Gap for NAD+ Injections
There is currently no published clinical evidence demonstrating the safety, efficacy, or clinical benefit of NAD+ administered via subcutaneous or intramuscular injection.
Subcutaneous injections typically deliver just 20mg of NAD+ per dose, which is far below even IV infusion doses of 500mg. And the evidence for IV NAD+ therapy itself is extremely limited. If 500mg infused directly into a vein does not reliably raise intracellular levels, the case for 20mg under the skin is difficult to defend on current evidence.
What the Clinical Data Points to Instead
If patches and injections both lack trial evidence for intracellular improvement, what does the research support?
The answer is NAD+ precursors delivered orally, specifically molecules like NMN and nicotinamide riboside (NR) that are small enough to enter cells, or that convert into forms that can.
Why NAD+ Precursors Work Differently
Unlike NAD+ itself, precursor molecules are designed to raise intracellular levels through a different mechanism. NR can cross cell membranes directly and is converted to NAD+ inside the cell. NMN is converted to NR outside the cell first, enters the cell, then reconverts to NMN and ultimately to NAD+. Both pathways have been studied in multiple randomized controlled trials in humans, with consistent findings showing meaningful increases in intracellular NAD+ levels.
This is a fundamentally different approach than delivering NAD+ directly by patch or injection. Precursors give cells the raw materials to build NAD+ from the inside, rather than trying to deliver a molecule that cannot reliably get through the cell membrane in the first place.
The Multi-Pathway Advantage
Formulation quality matters as much as precursor choice. Research comparing single-ingredient NAD+ precursors against multi-pathway formulas shows a meaningful gap in outcomes.
In Jinfiniti’s own clinical trial, 85% of participants reached optimal intracellular NAD+ levels (40–100 μM) within four weeks of supplementing with Vitality NAD+ Booster, a formula combining NMN, niacinamide, creatine monohydrate, and D-Ribose.
NAD+ levels doubled on average across the group. Clinical data from a separate functional medicine clinic comparing patients on subcutaneous NAD+ injections against the Vitality formula found that not a single patient on injections reached the optimal intracellular range, while the majority on the oral formula did.
As Dr. She explains: “The goal isn’t a specific milligram dose. It’s reaching and sustaining the optimal intracellular range of 40 to 100 μM. And the only way to know whether any method is actually getting you there is to measure it.”
How to Know If Any NAD Treatment Is Working
Whether you’re using patches, injections, or an oral formula, symptom tracking has real limits. Energy and cognitive clarity can shift for many reasons that have nothing to do with NAD+. Suboptimal levels can also persist without obvious symptoms.
The honest answer is that intracellular testing is the only reliable way to evaluate whether an intervention is working. You need an actual number in the 40–100 μM range, a baseline to compare against, and a way to confirm whether your approach is moving the needle before committing to a protocol long term.
Jinfiniti’s Intracellular NAD® Test is a CLIA-certified, at-home finger-prick test with results delivered within one week. It is the same test used in the clinical trials referenced above. For guidance on how to interpret results and adjust dosing from there, Jinfiniti’s NAD+ dosage guide walks through the data in plain terms.
RELATED READING
- NAD+ vs Peptides: What Works Better for Cellular Health?
- Urolithin A vs NAD: Which Is Better for Longevity?
- NAD vs Methylene Blue: What the Research Shows
Frequently Asked Questions
Are NAD+ patches FDA-approved?
No. NAD+ patches are sold as supplements, not pharmaceutical products. They have not been approved by the FDA for any therapeutic indication and are not subject to the same evidence requirements as medications. Marketing claims about clinical efficacy should be read with that in mind.
Do NAD+ injections require a prescription?
This depends on the provider and jurisdiction. Some clinics offer NAD+ injections under physician oversight; others operate in less regulated settings. Because there are no established standards for SC or IM NAD+ injection protocols, practices vary widely between providers.
Can you combine patches or injections with oral NAD+ supplements?
Some people do, but there is no clinical evidence guiding combined use. Given that the evidence base for patches and injections is limited, adding them to a proven oral formula does not meaningfully change the picture based on current research. A cleaner starting point is testing your baseline intracellular levels, starting with an evidence-backed formula, and measuring again after four weeks.
How long do NAD+ injection effects last?
Provider marketing often suggests effects lasting several days. There is no published clinical trial data confirming this for subcutaneous or intramuscular NAD+ injections specifically. IV infusions raise circulating NAD+ temporarily, but those effects reflect blood concentration, not verified intracellular improvement.
What side effects are associated with NAD+ patches and injections?
Patches can cause skin irritation, which is more common in people with sensitive skin. Injections may produce redness, tenderness, or discomfort at the injection site. IV infusions carry a more significant profile, including nausea, cramping, chest tightness, and anxiety. These risks are among the reasons leading researchers recommend oral precursors over injectable NAD+.
How do I know if my NAD+ levels are actually low?
Testing is the only reliable way to find out. The optimal intracellular NAD+ range is 40 to 100 μM. Many people fall below this threshold by their 40s or earlier, often without clear symptoms. An at-home intracellular NAD+ test gives you a baseline and a way to track whether any intervention is actually working over time.
















